JP2013525332A5 - - Google Patents

Download PDF

Info

Publication number
JP2013525332A5
JP2013525332A5 JP2013505469A JP2013505469A JP2013525332A5 JP 2013525332 A5 JP2013525332 A5 JP 2013525332A5 JP 2013505469 A JP2013505469 A JP 2013505469A JP 2013505469 A JP2013505469 A JP 2013505469A JP 2013525332 A5 JP2013525332 A5 JP 2013525332A5
Authority
JP
Japan
Prior art keywords
strand
sequence
composition
nucleotides
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013505469A
Other languages
English (en)
Japanese (ja)
Other versions
JP5857378B2 (ja
JP2013525332A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2011/056299 external-priority patent/WO2011131707A1/en
Publication of JP2013525332A publication Critical patent/JP2013525332A/ja
Publication of JP2013525332A5 publication Critical patent/JP2013525332A5/ja
Application granted granted Critical
Publication of JP5857378B2 publication Critical patent/JP5857378B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013505469A 2010-04-23 2011-04-20 ベータ−ＥＮａＣ−関連疾患を処置するための有機組成物 Expired - Fee Related JP5857378B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US32737910P 2010-04-23 2010-04-23
US61/327,379 2010-04-23
US33339810P 2010-05-11 2010-05-11
US61/333,398 2010-05-11
PCT/EP2011/056299 WO2011131707A1 (en) 2010-04-23 2011-04-20 ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014085797A Division JP5976032B2 (ja) 2010-04-23 2014-04-17 ベータ−ＥＮａＣ−関連疾患を処置するための有機組成物

Publications (3)

Publication Number Publication Date
JP2013525332A JP2013525332A (ja) 2013-06-20
JP2013525332A5 true JP2013525332A5 (https=) 2014-06-05
JP5857378B2 JP5857378B2 (ja) 2016-02-10

Family

ID=44227799

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2013505469A Expired - Fee Related JP5857378B2 (ja) 2010-04-23 2011-04-20 ベータ−ＥＮａＣ−関連疾患を処置するための有機組成物
JP2014085797A Expired - Fee Related JP5976032B2 (ja) 2010-04-23 2014-04-17 ベータ−ＥＮａＣ−関連疾患を処置するための有機組成物
JP2016141325A Expired - Fee Related JP6290316B2 (ja) 2010-04-23 2016-07-19 ベータ−ＥＮａＣ−関連疾患を処置するための有機組成物
JP2018019887A Expired - Fee Related JP6577073B2 (ja) 2010-04-23 2018-02-07 ベータ−ＥＮａＣ−関連疾患を処置するための有機組成物
JP2019150816A Pending JP2019214604A (ja) 2010-04-23 2019-08-21 ベータ−ＥＮａＣ−関連疾患を処置するための有機組成物
JP2021165417A Pending JP2022003089A (ja) 2010-04-23 2021-10-07 ベータ−ＥＮａＣ−関連疾患を処置するための有機組成物

Family Applications After (5)

Application Number Title Priority Date Filing Date
JP2014085797A Expired - Fee Related JP5976032B2 (ja) 2010-04-23 2014-04-17 ベータ−ＥＮａＣ−関連疾患を処置するための有機組成物
JP2016141325A Expired - Fee Related JP6290316B2 (ja) 2010-04-23 2016-07-19 ベータ−ＥＮａＣ−関連疾患を処置するための有機組成物
JP2018019887A Expired - Fee Related JP6577073B2 (ja) 2010-04-23 2018-02-07 ベータ−ＥＮａＣ−関連疾患を処置するための有機組成物
JP2019150816A Pending JP2019214604A (ja) 2010-04-23 2019-08-21 ベータ−ＥＮａＣ−関連疾患を処置するための有機組成物
JP2021165417A Pending JP2022003089A (ja) 2010-04-23 2021-10-07 ベータ−ＥＮａＣ−関連疾患を処置するための有機組成物

Country Status (15)

Country Link
US (10) US8344127B2 (https=)
EP (3) EP2561077B1 (https=)
JP (6) JP5857378B2 (https=)
KR (4) KR20190122893A (https=)
CN (2) CN102985544A (https=)
AR (1) AR081082A1 (https=)
AU (1) AU2011244335B2 (https=)
BR (1) BR112012027080A2 (https=)
CA (2) CA2797051C (https=)
DK (1) DK2561077T3 (https=)
EA (1) EA034363B1 (https=)
ES (1) ES2574204T3 (https=)
MX (2) MX383583B (https=)
TW (1) TWI434692B (https=)
WO (1) WO2011131707A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2561077T3 (en) 2010-04-23 2016-08-01 Arrowhead Res Corp Organic compositions for the treatment of beta-ENaC-related diseases
CN102397279B (zh) * 2011-11-18 2012-10-31 新乡医学院 无羁萜-3β-醇在制备抗血管性痴呆的药物中的应用
RS54944B1 (sr) 2012-07-12 2016-11-30 Proqr Therapeutics Ii Bv Oligonukleotidi za pravljenje promena u sekvencama ciljanih rnk molekula prisutnih u živoj ćeliji
WO2015131161A2 (en) 2014-02-28 2015-09-03 Attends Healthcare Products, Inc. Absorbent article with multi-layer folded absorbent core
CN109475552B (zh) * 2016-08-09 2022-04-05 上海药苑生物科技有限公司 用于食欲控制和体重管理的方法和组合物
WO2018112229A1 (en) 2016-12-14 2018-06-21 Eam Corporation Absorbent laminates, absorbent cores and disposable articles utilizing the absorbent laminates, and related methods
MX2020012801A (es) 2018-05-28 2021-03-25 Attends Healthcare Products Inc Laminado con capa de sequedad para articulos absorbentes.
CN109364248B (zh) * 2018-10-16 2021-05-18 哈尔滨医科大学 ENaC及其抑制剂在预防、缓解和/或治疗动脉粥样硬化中的应用
TW202130809A (zh) * 2019-10-29 2021-08-16 美商愛羅海德製藥公司 用於抑制β-ENaC表現之RNAi藥劑、其組合物及使用方法
WO2021188906A1 (en) * 2020-03-19 2021-09-23 Nature's Toolbox, Inc. Novel mrna-based covid-19 multi-valent vaccine and methods of scaled production of the same
CN114149492A (zh) * 2020-08-21 2022-03-08 中国人民解放军军事科学院军事医学研究院 一种用于预防甲型流感病毒感染的HA-mRNA疫苗

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6696561B1 (en) 1909-07-09 2004-02-24 Basf Aktiengesellschaft Corynebacterium glutamicum genes encoding proteins involved in membrane synthesis and membrane transport
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US5030453A (en) 1983-03-24 1991-07-09 The Liposome Company, Inc. Stable plurilamellar vesicles
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5032401A (en) 1989-06-15 1991-07-16 Alpha Beta Technology Glucan drug delivery system and adjuvant
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US6977244B2 (en) 1996-10-04 2005-12-20 Board Of Regents, The University Of Texas Systems Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
US5891467A (en) 1997-01-31 1999-04-06 Depotech Corporation Method for utilizing neutral lipids to modify in vivo release from multivesicular liposomes
CA2361201A1 (en) 1999-01-28 2000-08-03 Medical College Of Georgia Research Institute, Inc. Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
EP1272630A2 (en) 2000-03-16 2003-01-08 Genetica, Inc. Methods and compositions for rna interference
ES2336887T5 (es) 2000-03-30 2019-03-06 Whitehead Inst Biomedical Res Mediadores de interferencia por ARN específicos de secuencias de ARN
US6680068B2 (en) 2000-07-06 2004-01-20 The General Hospital Corporation Drug delivery formulations and targeting
WO2003070910A2 (en) * 2002-02-20 2003-08-28 Ribozyme Pharmaceuticals, Incorporated INHIBITION OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) AND VEGF RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
EP1399189A1 (en) 2001-06-11 2004-03-24 Universite De Montreal Compositions and methods for enhancing nucleic acid transfer into cells
JP5170934B2 (ja) 2001-08-16 2013-03-27 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 改良ｄｎａリポフェクションならびに／または徐放性プロドラッグおよび薬物療法のための試薬の合成と使用
EP1478655A4 (en) 2001-12-31 2006-05-10 Algos Therapeutics Inc METHODS AND SUBSTANCES FOR ENAC-BETA MODULATION
EP1519714B1 (en) 2002-06-28 2010-10-20 Protiva Biotherapeutics Inc. Method and apparatus for producing liposomes
US20050008617A1 (en) 2002-09-28 2005-01-13 Massachusetts Institute Of Technology Compositions and methods for delivery of short interfering RNA and short hairpin RNA
AU2003295600A1 (en) * 2002-11-14 2004-06-15 Dharmacon, Inc. Functional and hyperfunctional sirna
EP1585756B1 (en) 2002-11-26 2010-04-21 University of Massachusetts Delivery of sirnas
US20040208921A1 (en) 2003-01-14 2004-10-21 Ho Rodney J. Y. Lipid-drug formulations and methods for targeted delivery of lipid-drug complexes to lymphoid tissues
CN1842709A (zh) * 2003-07-10 2006-10-04 塞诺米克斯公司 使用表达人的ENaC的卵母细胞的改进的电生理测定法和用于在使用膜电位报告染料的测定中提高ENaC增强子功效的PHENAMIL的用途
CA2532228C (en) 2003-07-16 2017-02-14 Protiva Biotherapeutics, Inc. Lipid encapsulated interfering rna
EP1660657A1 (en) 2003-08-28 2006-05-31 Novartis AG Interfering rna duplex having blunt-ends and 3'-modifications
WO2005116204A1 (ja) * 2004-05-11 2005-12-08 Rnai Co., Ltd. Ｒｎａ干渉を生じさせるポリヌクレオチド、および、これを用いた遺伝子発現抑制方法
US7740861B2 (en) 2004-06-16 2010-06-22 University Of Massachusetts Drug delivery product and methods
CA2622671C (en) 2005-09-16 2020-12-22 Devgen Nv Methods for controlling pests using rnai
CN101346393B (zh) 2005-11-02 2015-07-22 普洛体维生物治疗公司 修饰的siRNA分子及其应用
US7389426B2 (en) 2005-11-29 2008-06-17 Research In Motion Limited Mobile software terminal identifier
GB0608838D0 (en) 2006-05-04 2006-06-14 Novartis Ag Organic compounds
KR101629017B1 (ko) 2007-05-22 2016-06-10 아크투루스 쎄라퓨틱스, 인크. 히드록시메틸 치환된 ｒｎａ 올리고뉴클레오티드 및 ｒｎａ 복합체
AR066984A1 (es) 2007-06-15 2009-09-23 Novartis Ag Inhibicion de la expresion de la subunidad alfa del canal epitelial de sodio (enac) por medio de arni (arn de interferencia)
ES2535419T3 (es) 2007-12-27 2015-05-11 Protiva Biotherapeutics Inc. Silenciamiento de expresión de quinasa tipo polo usando ARN interferente
DK2561077T3 (en) 2010-04-23 2016-08-01 Arrowhead Res Corp Organic compositions for the treatment of beta-ENaC-related diseases

Similar Documents

Publication Publication Date Title
JP2013525332A5 (https=)
JP2013514321A5 (https=)
JP2014525435A5 (https=)
JP2015517466A5 (https=)
JP2016511256A5 (https=)
Ezzat et al. Self-assembly into nanoparticles is essential for receptor mediated uptake of therapeutic antisense oligonucleotides
CN103328633B (zh) 诱导rna干扰的核酸分子及其用途
US20210238601A1 (en) Oligonucleotide Conjugates
Ma et al. Recent advances of discrete coordination complexes and coordination polymers in drug delivery
JP2024028909A (ja) ハンチンチンｍＲＮＡをターゲティングするオリゴヌクレオチド化合物
AU2015252917B2 (en) Compositions and methods for modulating PKK expression
AU2015252841B2 (en) Compositions and methods for modulating growth hormone receptor expression
WO2009120887A3 (en) Compositions and methods for tissue-specific rnai delivery in vivo
ES2984631T3 (es) Composiciones y procedimientos para disminuir la expresión de tau
JP2017518045A5 (https=)
JP2013516190A5 (https=)
JP2016116520A5 (https=)
JP2015500835A5 (https=)
JP2009517048A5 (https=)
JP2007533323A (ja) 哺乳類の細胞における遺伝子発現を調節するための、二本鎖ｒｎａまたは二本鎖ハイブリッド核酸の送達を増強するための方法および組成物
JP2016523564A5 (https=)
JP2015523854A5 (https=)
JP2012050438A5 (https=)
JP2019503199A5 (https=)
JP2016501513A5 (https=)